CN120983618A - 用奥滨尤妥珠单抗对cd20阳性b细胞淋巴瘤的治疗 - Google Patents

用奥滨尤妥珠单抗对cd20阳性b细胞淋巴瘤的治疗

Info

Publication number
CN120983618A
CN120983618A CN202511095071.9A CN202511095071A CN120983618A CN 120983618 A CN120983618 A CN 120983618A CN 202511095071 A CN202511095071 A CN 202511095071A CN 120983618 A CN120983618 A CN 120983618A
Authority
CN
China
Prior art keywords
tuozhu
mab
obbine
administration
hour
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202511095071.9A
Other languages
English (en)
Chinese (zh)
Inventor
M·威戈
M·莫巴舍尔
C-Y·林
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
F Hoffmann La Roche AG
Original Assignee
F Hoffmann La Roche AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=64362606&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CN120983618(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by F Hoffmann La Roche AG filed Critical F Hoffmann La Roche AG
Publication of CN120983618A publication Critical patent/CN120983618A/zh
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2887—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against CD20
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Saccharide Compounds (AREA)
  • Steroid Compounds (AREA)
CN202511095071.9A 2017-10-19 2018-10-19 用奥滨尤妥珠单抗对cd20阳性b细胞淋巴瘤的治疗 Pending CN120983618A (zh)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201762574297P 2017-10-19 2017-10-19
US62/574,297 2017-10-19
CN201880067120.XA CN111212854A (zh) 2017-10-19 2018-10-19 用奥滨尤妥珠单抗对cd20阳性b细胞淋巴瘤的治疗
PCT/JP2018/038924 WO2019017499A2 (en) 2017-10-19 2018-10-19 PHARMACEUTICAL COMPOSITION

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
CN201880067120.XA Division CN111212854A (zh) 2017-10-19 2018-10-19 用奥滨尤妥珠单抗对cd20阳性b细胞淋巴瘤的治疗

Publications (1)

Publication Number Publication Date
CN120983618A true CN120983618A (zh) 2025-11-21

Family

ID=64362606

Family Applications (2)

Application Number Title Priority Date Filing Date
CN202511095071.9A Pending CN120983618A (zh) 2017-10-19 2018-10-19 用奥滨尤妥珠单抗对cd20阳性b细胞淋巴瘤的治疗
CN201880067120.XA Withdrawn CN111212854A (zh) 2017-10-19 2018-10-19 用奥滨尤妥珠单抗对cd20阳性b细胞淋巴瘤的治疗

Family Applications After (1)

Application Number Title Priority Date Filing Date
CN201880067120.XA Withdrawn CN111212854A (zh) 2017-10-19 2018-10-19 用奥滨尤妥珠单抗对cd20阳性b细胞淋巴瘤的治疗

Country Status (14)

Country Link
US (2) US12129304B2 (enExample)
EP (2) EP4520347A3 (enExample)
JP (2) JP6860652B2 (enExample)
KR (2) KR20240157135A (enExample)
CN (2) CN120983618A (enExample)
AU (2) AU2018303836B2 (enExample)
BR (1) BR112020007731A2 (enExample)
CA (1) CA3079374A1 (enExample)
ES (1) ES3005784T3 (enExample)
IL (2) IL321935A (enExample)
MX (2) MX419643B (enExample)
PL (1) PL3697818T3 (enExample)
TW (2) TWI828593B (enExample)
WO (1) WO2019017499A2 (enExample)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20240157135A (ko) * 2017-10-19 2024-10-31 에프. 호프만-라 로슈 아게 오비누투주맙에 의한 cd20-양성 b 세포 림프종의 치료
AR122307A1 (es) * 2019-10-04 2022-08-31 Chugai Pharmaceutical Co Ltd Agente de supresión de la proliferación celular de cáncer cd20 positivo tolerante a obinutuzumab, y composición farmacéutica, medicamento, fabricación, procedimiento de supresión de la proliferación celular, procedimiento de tratamiento, anticuerpo anti-cd20 de tipo ii, compuesto, sus combinaciones, y agente potenciador y agente inductor, relacionados con estos
WO2023042679A1 (ja) 2021-09-17 2023-03-23 キヤノン株式会社 送電装置および受電装置

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TR201809892T4 (tr) 2003-11-05 2018-07-23 Roche Glycart Ag Fc reseptörüne bağlanma afinitesi ve artırılmış efektör fonksiyonu bulunan antijen bağlayan moleküller.
AU2008340429C1 (en) 2007-12-21 2016-09-08 F. Hoffmann-La Roche Ag Antibody formulation
SMT202200285T1 (it) * 2014-08-11 2022-09-14 Acerta Pharma Bv Combinazioni terapeutiche di un inibitore di btk, un inibitore di pd-1 e/o un inibitore di pd-l1
WO2017100722A1 (en) * 2015-12-09 2017-06-15 Cedars-Sinai Medical Center Methods for treating nephrotic syndrome
CN108395482B (zh) 2017-02-08 2021-02-05 西比曼生物科技（香港）有限公司 一种靶向cd20抗原嵌合抗原受体的构建及其工程化t细胞的活性鉴定
EP3656814B1 (en) 2017-07-21 2025-12-24 The Yokohama Rubber Co., Ltd. Pneumatic tire
KR20240157135A (ko) * 2017-10-19 2024-10-31 에프. 호프만-라 로슈 아게 오비누투주맙에 의한 cd20-양성 b 세포 림프종의 치료

Also Published As

Publication number Publication date
BR112020007731A2 (pt) 2020-10-20
US20250026847A1 (en) 2025-01-23
MX2020003418A (es) 2020-07-20
KR20200067196A (ko) 2020-06-11
EP4520347A3 (en) 2025-06-04
JP2021152002A (ja) 2021-09-30
JP2019528282A (ja) 2019-10-10
IL273909B1 (en) 2025-08-01
JP7370357B2 (ja) 2023-10-27
TW201922284A (zh) 2019-06-16
US12129304B2 (en) 2024-10-29
US20200299398A1 (en) 2020-09-24
ES3005784T3 (en) 2025-03-17
KR102766089B1 (ko) 2025-02-13
IL273909A (en) 2020-05-31
TWI805630B (zh) 2023-06-21
IL273909B2 (en) 2025-12-01
EP3697818A2 (en) 2020-08-26
TW202342099A (zh) 2023-11-01
EP3697818B1 (en) 2024-11-27
PL3697818T3 (pl) 2025-03-24
IL321935A (en) 2025-09-01
AU2025205481A1 (en) 2025-08-07
CA3079374A1 (en) 2019-01-24
KR20240157135A (ko) 2024-10-31
CN111212854A (zh) 2020-05-29
MX419643B (es) 2025-01-14
JP6860652B2 (ja) 2021-04-21
AU2018303836A1 (en) 2020-05-14
WO2019017499A2 (en) 2019-01-24
TWI828593B (zh) 2024-01-01
AU2018303836B2 (en) 2025-04-17
EP4520347A2 (en) 2025-03-12
MX2024009217A (es) 2024-11-08
WO2019017499A3 (en) 2019-02-21

Similar Documents

Publication Publication Date Title
US12090183B2 (en) Methods of treating solid or lymphatic tumors by combination therapy
US20220125864A1 (en) Methods of treating solid or lymphatic tumors by combination therapy
US20250026847A1 (en) Treatment of cd20-positive b-cell lymphoma with obinutuzumab
EA031489B1 (ru) Способ лечения ревматоидного артрита
JP7670713B2 (ja) 皮下投与のための抗ｃｄ３８抗体の製剤
CN114026126A (zh) 抗半乳糖凝集素-9抗体及其用途
KR20200078483A (ko) 간암 치료를 위한 조성물 및 방법
TW202034925A (zh) Ｃｄｋ４／６抑制劑聯合免疫治療在製備治療淋巴瘤的藥物中的用途
HK40031517A (en) Treatment of cd20-positive b-cell lymphoma with obituzumab
JP2024519449A (ja) がん治療における使用のための抗ガレクチン－９抗体と化学療法剤との併用
CN117769435A (zh) 通过施用抗cd127剂治疗cd127阳性癌症的方法
CN118871128A (zh) 抗tim-3抗体与抗pd-l1抗体的药物组合
EP4494654A1 (en) Pharmaceutical composition of anti-tim-3 antibody and hypomethylating agent
US20240025987A1 (en) Use of anti-il-27 antibodies
CN118324910A (zh) Ccr8抗体的应用
CN120093930A (zh) 用于胆管癌免疫治疗的组合物及其应用
HK40074716A (en) Combined cancer therapy of anti-galectin-9 antibodies and chemotherapeutics
HK40069657A (en) Anti-galectin-9 antibodies and uses thereof

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination